Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2022

21-08-2021 | Mood Disorders | Original Article

Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis

Authors: Hirsh D. Trivedi, Sebastian Niezen, Z. Gordon Jiang, Elliot B. Tapper

Published in: Digestive Diseases and Sciences | Issue 8/2022

Login to get access

Abstract

Background & Aim

Liver fibrosis is associated with poor patient-reported outcomes (PROs), but the impact of steatosis is unknown. We aimed to evaluate the impact of steatosis on PROs independent of liver fibrosis.

Methods

We evaluated the impact of steatosis, measured by Controlled-Attenuation Parameter (CAP) on transient elastography, and PROs using the 2017–2018 National Health and Nutrition Examination Survey (NHANES) database. We used univariate and multivariate logistic and ordinal regression to evaluate categorical CAP score with PROs measuring physical disability, general health and depression.

Results

Of 4,509 participants included, 38% had severe steatosis (> 280 dB/m). Those with severe steatosis were older and more likely to be male (56% vs. 43% and 51%). On univariate analysis, severe steatosis was associated with more difficulty walking (P = 0.01), dressing (P = 0.005), lifting objects (P = 0.02), bending (P < 0.001), and moving large objects (P = 0.0006). After multivariate adjustment, severe steatosis remained associated with difficulty lifting objects (odds ratio [OR]: 1.7, 95% confidence interval [CI]: 1.2–2.4, P = 0.01) and difficulty bending (OR: 1.8, 95% CI: 1.2–2.7, P = 0.006). Severe steatosis increased risk of having any of the disabilities (OR: 1.7, 95% CI: 1.2–2.4, P = 0.008) and had higher ordinal disability index (OR: 1.6, 95% CI: 1.2–2.2, P = 0.007). Lastly, severe steatosis was also associated with worse self-perceived health status (OR: 1.5, 95% CI: 1.2–1.9, P = 0.002), while general health compared to one year ago and depression trended toward significance.

Conclusion

Patients with severe steatosis are at increased risk of physical disability and have worse self-perceived health status independent of liver fibrosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Younossi ZM, Stepanova M, Younossi Y et al. Epidemiology Of chronic liver diseases in the USA in the past three decades. Gut. 2020;69:564–568.CrossRef Younossi ZM, Stepanova M, Younossi Y et al. Epidemiology Of chronic liver diseases in the USA in the past three decades. Gut. 2020;69:564–568.CrossRef
2.
go back to reference Asrani SK, Devarbhavi H, Eaton J et al. Burden of liver diseases in the World. J Hepatol. 2019;70:151–171.CrossRef Asrani SK, Devarbhavi H, Eaton J et al. Burden of liver diseases in the World. J Hepatol. 2019;70:151–171.CrossRef
3.
go back to reference Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association. 2019. Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association. 2019.
4.
go back to reference Younossi Z, Anstee QM, Marietti M et al. Global burden of nafld and nash: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology & Hepatology. 2018;15:11–20.CrossRef Younossi Z, Anstee QM, Marietti M et al. Global burden of nafld and nash: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology & Hepatology. 2018;15:11–20.CrossRef
5.
go back to reference Shrestha D, Rathi S, Grover S et al. Factors affecting psychological burden on the informal caregiver of patients with cirrhosis: looking beyond the patient. Journal of Clinical and Experimental Hepatology. 2020;10:9–16.CrossRef Shrestha D, Rathi S, Grover S et al. Factors affecting psychological burden on the informal caregiver of patients with cirrhosis: looking beyond the patient. Journal of Clinical and Experimental Hepatology. 2020;10:9–16.CrossRef
6.
go back to reference Younossi ZM, Henry L. economic and quality-of-life implications of non-alcoholic fatty liver disease. Pharmacoeconomics. 2015;33:1245–1253.CrossRef Younossi ZM, Henry L. economic and quality-of-life implications of non-alcoholic fatty liver disease. Pharmacoeconomics. 2015;33:1245–1253.CrossRef
7.
go back to reference Tapper EB, Baki J, Parikh ND et al. Frailty, psychoactive medications, and cognitive dysfunction are associated with poor patient-reported outcomes in cirrhosis. Hepatology (Baltimore, Md). 2019;69:1676–1685.CrossRef Tapper EB, Baki J, Parikh ND et al. Frailty, psychoactive medications, and cognitive dysfunction are associated with poor patient-reported outcomes in cirrhosis. Hepatology (Baltimore, Md). 2019;69:1676–1685.CrossRef
8.
go back to reference Younossi ZM, Golabi P, Henry L. A comprehensive review of patient-reported outcomes in patients with chronic liver diseases. Journal Of Clinical Gastroenterology. 2019;53:331–341.CrossRef Younossi ZM, Golabi P, Henry L. A comprehensive review of patient-reported outcomes in patients with chronic liver diseases. Journal Of Clinical Gastroenterology. 2019;53:331–341.CrossRef
9.
go back to reference Balp MM, Krieger N, Przybysz R et al. The burden of non-alcoholic steatohepatitis (nash) among patients from Europe: A real-world patient-reported outcomes study. Jhep Rep. 2019;1:154–161.CrossRef Balp MM, Krieger N, Przybysz R et al. The burden of non-alcoholic steatohepatitis (nash) among patients from Europe: A real-world patient-reported outcomes study. Jhep Rep. 2019;1:154–161.CrossRef
10.
go back to reference Golabi P, Otgonsuren M, Cable R et al. Non-alcoholic fatty liver disease (nafld) is associated with impairment of health related quality of life (hrqol). Health Qual Life Outcomes. 2016;14:18.CrossRef Golabi P, Otgonsuren M, Cable R et al. Non-alcoholic fatty liver disease (nafld) is associated with impairment of health related quality of life (hrqol). Health Qual Life Outcomes. 2016;14:18.CrossRef
11.
go back to reference Gerber Y, Vanwagner LB, Yaffe K et al. Non-alcoholic fatty liver disease and cognitive function in middle-aged adults: the cardia study. Bmc Gastroenterology. 2021;21:96.CrossRef Gerber Y, Vanwagner LB, Yaffe K et al. Non-alcoholic fatty liver disease and cognitive function in middle-aged adults: the cardia study. Bmc Gastroenterology. 2021;21:96.CrossRef
12.
go back to reference Seo SW, Gottesman RF, Clark JM et al. Nonalcoholic fatty liver disease is associated with cognitive function in adults. Neurology. 2016;86:1136–1142.CrossRef Seo SW, Gottesman RF, Clark JM et al. Nonalcoholic fatty liver disease is associated with cognitive function in adults. Neurology. 2016;86:1136–1142.CrossRef
13.
go back to reference Weinstein G, Davis-Plourde K, Himali JJ et al. Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: the framingham study. Liver International: Official Journal of the International Association for the Study of the Liver. 2019;39:1713–1721.CrossRef Weinstein G, Davis-Plourde K, Himali JJ et al. Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: the framingham study. Liver International: Official Journal of the International Association for the Study of the Liver. 2019;39:1713–1721.CrossRef
14.
go back to reference Cortesi PA, Conti S, Scalone L et al. Health related quality of life in chronic liver diseases. Liver International : Official Journal of the International Association for the Study of the Liver. 2020;40:2630–2642.CrossRef Cortesi PA, Conti S, Scalone L et al. Health related quality of life in chronic liver diseases. Liver International : Official Journal of the International Association for the Study of the Liver. 2020;40:2630–2642.CrossRef
15.
go back to reference Paik JM, Golabi P, Younossi Y et al. The growing burden of disability related to nonalcoholic fatty liver disease: data from the global burden of disease 2007–2017. Hepatology Communications. 2020;4:1769–1780.CrossRef Paik JM, Golabi P, Younossi Y et al. The growing burden of disability related to nonalcoholic fatty liver disease: data from the global burden of disease 2007–2017. Hepatology Communications. 2020;4:1769–1780.CrossRef
16.
go back to reference Sung JC, Bosh C, Wyatt B et al. Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center. Journal Of Viral Hepatitis. 2020;27:350–359.CrossRef Sung JC, Bosh C, Wyatt B et al. Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center. Journal Of Viral Hepatitis. 2020;27:350–359.CrossRef
17.
go back to reference Curtin LR, Mohadjer LK, Dohrmann SM, et al. The national health and nutrition examination survey: sample design, 1999–2006. Vital Health Stat 2. 2012;(155):1–39. Curtin LR, Mohadjer LK, Dohrmann SM, et al. The national health and nutrition examination survey: sample design, 1999–2006. Vital Health Stat 2. 2012;(155):1–39.
18.
go back to reference Karlas T, Petroff D, Sasso M et al. Individual patient data meta-analysis of controlled attenuation parameter (cap) technology for assessing steatosis. Journal Of Hepatology. 2017;66:1022–1030.CrossRef Karlas T, Petroff D, Sasso M et al. Individual patient data meta-analysis of controlled attenuation parameter (cap) technology for assessing steatosis. Journal Of Hepatology. 2017;66:1022–1030.CrossRef
19.
go back to reference Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.E310. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.E310.
20.
go back to reference Tapper EB, Lok ASF. Use of liver imaging and biopsy in clinical practice. N Engl J Med. Vol 377. United States2017:2296–2297. Tapper EB, Lok ASF. Use of liver imaging and biopsy in clinical practice. N Engl J Med. Vol 377. United States2017:2296–2297.
21.
go back to reference Newton Jl, Jones De, Henderson E, Et Al. Fatigue In Non-Alcoholic Fatty Liver Disease (Nafld) Is Significant And Associates With Inactivity And Excessive Daytime Sleepiness But Not With Liver Disease Severity Or Insulin Resistance. Gut. 2008;57(6):807–813. Newton Jl, Jones De, Henderson E, Et Al. Fatigue In Non-Alcoholic Fatty Liver Disease (Nafld) Is Significant And Associates With Inactivity And Excessive Daytime Sleepiness But Not With Liver Disease Severity Or Insulin Resistance. Gut. 2008;57(6):807–813.
Metadata
Title
Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis
Authors
Hirsh D. Trivedi
Sebastian Niezen
Z. Gordon Jiang
Elliot B. Tapper
Publication date
21-08-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07228-3

Other articles of this Issue 8/2022

Digestive Diseases and Sciences 8/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine